AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02451358 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Inactivated Influenza Vaccine (2016-2017 NH formulation), No Preservative
Description: 0.25 mL, Intramuscular
Study NCT02451358 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Inactivated Influenza Vaccine (2016 SH formulation), No Preservative
Description: 0.5 mL, Intramuscular
Study NCT02451358 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Inactivated Influenza Vaccine (2015-2016 NH formulation), No Preservative
Description: 0.5 mL, Intramuscular
Study NCT02451358 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Inactivated Influenza Vaccine (2015 SH formulation), No Preservative
Description: 0.5 mL, Intramuscular
Study NCT03100019 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol
Study NCT03037008 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Perineal Sonography
Description: In a modified lithotomy position (supine position with elevated legs), probands will get an examination of their pelvic floor by using a common ultrasound probe head on the perineum. During the examination, the bladder should be filled with around 300ml. If patient appear with empty bladder, the examination can be repeated on an other date. During the examination, the pelvic floor will be observed during rest, coughing and valsalva-maneuver. One examination takes around 30minutes. During ultrasound, we want to illustrate the urethral mobility, the bladder neck opening and the urethral angle as well as the distance from the urethra to the symphysis.
Study NCT04180423 — intervention group
Intervention type: DEVICE
Intervention: Off-the-Shelf Implant Total Knee Replacement
Description: Total Knee Replacement, or knee arthroplasty, is a common surgical procedure performed to relieve the pain and disability resulting from osteoarthritis. In general, the surgery consists of replacing the diseased or damaged joint surfaces of the knee with metal and plastic components shaped to allow continued motion of the knee. Off-the-Shelf implants use standard sizing.
Study NCT03193905 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bairhugger Full Access Underbody Blanket
Description: 30 patients undergo new procedure with a Bairhugger Full Access Underbody Blanket
Study NCT04180423 — intervention group
Intervention type: DEVICE
Intervention: Customized Implant Total Knee Replacement
Description: Total Knee Replacement, or knee arthroplasty, is a common surgical procedure performed to relieve the pain and disability resulting from osteoarthritis. In general, the surgery consists of replacing the diseased or damaged joint surfaces of the knee with metal and plastic components shaped to allow continued motion of the knee. Customized implants are customized individually made knee implants which are designed specific to each patient's unique anatomy.
Study NCT03193905 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cotton blanket - control group
Description: 30 patients undergo standard procedure with a cotton blanket
Study NCT00782080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sedariston
Description: St. John´s Wort (100 mg) Valerian Extract (50 mg)
Study NCT00782080 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02400112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Vancomycin powder administered locally, intraoperatively at site of open fracture
Study NCT00435539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ocriplasmin
Description: Intravitreal injection of ocriplasmin solution containing 75µg of ocriplasmin.
Study NCT00435539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ocriplasmin
Description: Intravitreal injection of ocriplasmin solution containing 125µg of ocriplasmin with up to 2 additional (open label) 125µg ocriplasmin injection at 1 month interval.
Study NCT00435539 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: Intravitreal sham injection
Study NCT03047460 — intervention group
Intervention type: OTHER
Intervention: multimodal evoked potentials
Study NCT00231465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel (Taxotere®)
Description: Taxotere® will be administered to patients a maximum of 2 cycles, after a maximal response is achieved, and then discontinued.
Study NCT00231465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD1839
Description: ZD1839 will be continued until progression, or until trial closure, whichever comes first.
Study NCT01596244 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Microclinic
Description: Microclinics consist of 2-8 individuals from pre-existing social networks (friends, relatives, coworkers, neighbors, etc) that voluntarily participate in ongoing education and medical monitoring from local health care professionals, learning and practicing diabetes management strategies, sharing much-needed medical supplies, and exchanging social support in the form of regular microclinic meetings.
Study NCT03003897 — intervention group
Intervention type: OTHER
Intervention: Soluble Fiber
Description: Participants receiving soluble fiber.
Study NCT01894282 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy
Description: Manual Therapy Arm
Study NCT01894282 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: Manual Therapy Arm
Study NCT01894282 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mind Body Intervention
Description: Combination of manual therapy and cognitive behavioral therapy for pain.
Study NCT01462292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2402968 3mg/kg/week
Description: Comparison of 2 doses of GSK2402968
Study NCT01462292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2402968 6 mg/kg/week
Description: Comparison of 2 doses of GSK2402968
Study NCT01462292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match GSK2402968 3 mg/kg/week
Description: Matched placebo
Study NCT01462292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match GSK2402968 6 mg/kg/week
Description: Matched Placebo
Study NCT03145129 — intervention group
Intervention type: DEVICE
Intervention: Continuous Positive Airway Pressure
Description: Continuous Positive Airway Pressure
Study NCT00510692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eicosapentanoic Acid (EPA)
Description: 2 x 500mg EPA capsules twice daily for 6 months
Study NCT00510692 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopy
Description: Endoscopy with video and photographs at baseline and month 6.
Study NCT00510692 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Endoscopy
Description: Endoscopy with video and photographs at baseline and month 6.
Study NCT00510692 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsies taken
Description: 9 biopsies taken at baseline and month 6 from the rectum of normal mucosa for analysis of apoptosis (3 biopsies), cell proliferation (3 biopsies) and mucosal fatty acid levels (3 biopsies). Two biopsies taken at baseline and month 6 from polyps for cell proliferation (1 biopsy) and apoptosis (1 biopsy).
Study NCT00510692 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biopsies taken
Description: 9 biopsies taken at baseline and month 6 from the rectum of normal mucosa for analysis of apoptosis (3 biopsies), cell proliferation (3 biopsies) and mucosal fatty acid levels (3 biopsies). Two biopsies taken at baseline and month 6 from polyps for cell proliferation (1 biopsy) and apoptosis (1 biopsy).
Study NCT03003897 — intervention group
Intervention type: OTHER
Intervention: Placebo
Description: Participants receiving placebo.
Study NCT03563612 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cpap
Description: application of cpap to the non-dependent lung, during one lung ventilation
Study NCT00510692 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 x 500mg placebo capsules twice daily for 6 months
Study NCT01804361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haporine-S
Description: 1 or 2 drops twice a day at 12 hour interval for 12 weeks
Study NCT01804361 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Restasis (cyclosporine 0.05%)
Description: 1 or 2 drops twice a day at 12 hour interval for 12 weeks
Study NCT03591952 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suction-Driven Thoracentesis
Description: Thoracentesis is a procedure in which a needle is inserted into the pleural space between the lungs and the chest wall. This procedure is done to remove excess fluid, known as a pleural effusion, from the pleural space to help one breathe easier.
Study NCT03591952 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gravity-Driven Thoracentesis
Description: Thoracentesis is a procedure in which a needle is inserted into the pleural space between the lungs and the chest wall. This procedure is done to remove excess fluid, known as a pleural effusion, from the pleural space to help one breathe easier.
Study NCT00997685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine plus oxaliplatin
Description: Xeloda: 1000mg/m2 bid, d1-14, q3w, Oxaliplatin:130mg/m2 d1, q3w,~4 pre-operative cycles, 4 post-operative cycles
Study NCT02973815 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NU-HOME Intervention
Description: The NU-HOME family intervention program consists of seven monthly group sessions, individual goal setting calls and online materials to support the sessions. The intervention focuses on promoting healthful family meals where parents and children cook and eat together, healthful home food and physical activity environments, and being active together as a family.
Study NCT00907725 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: serum BhCG follow-up
Description: Subjects in this arm will receive medical abortion follow-up using BhCG blood draw
Study NCT00907725 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ultrasonographic follow-up
Description: Subjects in this arm will receive medical abortion follow-up by ultrasound
Study NCT04624932 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RR Digital Tool
Description: This is the intervention condition. Participants in this condition will take the RR digital tool available at https://outsideplay.ca.
Study NCT04624932 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Position Statement on Active Outdoor Play
Description: This is the control condition. Participants in this condition will read the position statement that summarizes the issues and research regarding children's access to outdoor play.
Study NCT04341753 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pulmonary rehabilitation
Description: the strength' measure of the deltoids, triceps and brachial biceps will be carried out by another technique: the 1-RM technique (with dumbbells);~- 2 other times, the strength' measure of the deltoids, triceps and brachial biceps will be carried out by handheld dynaometry.
Study NCT01563146 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Each participating centre will be requested to generate a coded list of all stool samples taken during the study period (June 1st 2006- May 31st 2007) and analysed for rotavirus, in children aged ≤5 years.
Study NCT02599948 — intervention group
Intervention type: OTHER
Intervention: no intervention
Study NCT01452425 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tourniquet
Description: Inflation of a tourniquet (pressure equal to the mean arterial pressure) obtaining a model of slight venous congestion and arterial hypoperfusion
Study NCT01452425 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INVOS assessment
Description: Near Infraread spectroscopy, non invasive
Study NCT01452425 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMG assessment
Description: Electromyography, non invasive
Study NCT03799120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin BID
Description: comparison of once daily versus twice daily tamsulosin
Study NCT03799120 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tamsulosin BID
Description: comparison of once daily versus twice daily tamsulosin
Study NCT01962636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m\^2 IV of Fludarabine will be given over 1 hour on days -8, -7, and -6 pre-UCB transplant.
Study NCT01962636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 60 mg/kg IV of Cyclophosphamide will be given over 2 hours on days -7 and -6 pre-UCB transplant.
Study NCT03799120 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00666341 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo: Al(OH)3-Placebos with histamine-dihydrochloride analogue Allergen-Adsorbate rPhleum strengthes 1 to 4.
Study NCT00666341 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rPhleum
Description: Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 1 (20 μg)
Study NCT01962636 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: 165 cGy of total body irradiation will be given twice a day on days -4, -3, -2, and -1.
Study NCT01962636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Description: Cyclosporine A (CSA) will start day -3 and will be administered PO/IV maintaining a trough level between 200 and 400 ng/mL. For adults the initial dose will be 2.5 mg/kg IV over 1 hour every 12 hours. For children \< 40 kg the initial dose will be 2.5 mg/kg IV over 1 hour every 8 hours.
Study NCT01630785 — intervention group
Intervention type: DEVICE
Intervention: Intraoperative Neurophysiological Monitoring IONM
Description: Intraoperative Neurophysiological Monitoring IONM device. Manufacturer: Inomed, Emmendingen, Germany
Study NCT03055858 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ADO II AS (PDA closure)
Description: Closure of PDA using Amplatzer Duct Occluder II Additional Sizes (ADO II AS).
Study NCT01962636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenylate mofetil
Description: Mycophenylate mofetil (MMF) 3 gram/day IV/PO for patients who are ≥ 40 kg divided in 2 or 3 doses. Pediatric patient (\<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours beginning day -3.
Study NCT01962636 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical cord blood
Description: Pre-medications and UCB infusion will be per current institutional policies/guidelines. The infusion of the first UCB unit should begin within 15 minutes, and no later than 30 minutes after arrival on the Unit. If 2 units are used, both cords will be infused within 30-60 minutes of each other as deemed clinically safe by the BMT attending or designee.
Study NCT03699345 — intervention group
Intervention type: DEVICE
Intervention: Transcatheter Aortic Valve Replacement (TAVR)
Description: TAVR with the Edwards CENTERA THV System and accessories
Study NCT03075254 — intervention group
Intervention type: DEVICE
Intervention: fMRI for Spinal Cord Neuroimaging
Description: The subjects will be positioned supine and immobilized by means of a padded head support. The spinous process of the first thoracic vertebra (T1) will be aligned with the center of surface Neuro - coil. This coil will be employed for both transmission of radio-frequency (RF) pulses and detection of the magnetic resonance (MR) signal. A modified FLASH sequence will be employed to obtain Blood Oxygen Level Dependent (BOLD)-sensitive images of the spinal cord.
Study NCT00666341 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rPhleum
Description: Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 2 (40 μg)
Study NCT02694809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conjugated Estrogens/Bazedoxifene
Description: Given PO
Study NCT01575288 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100g maltose 1/day
Study NCT01575288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose trehalose
Description: 100g 1/day
Study NCT02005328 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tested product : DC161-DP0291
Description: Application of product in the mouth twice daily
Study NCT02005328 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tested product : DC161-DP0292
Description: Application of product in the mouth twice daily
Study NCT02005328 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tested product : DC161-DP0293
Description: Application of product in the mouth twice daily
Study NCT02005328 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reference product: solution for oromucosal sprays
Description: Application of product in the mouth twice daily
Study NCT03468543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine Hydrochloride MR Prototype Capsule Formulation A
Description: Memantine HCl MR capsule formulation will be administered orally in a single dose
Study NCT02694809 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02694809 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02694809 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02694809 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02694809 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO
Study NCT02694809 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02694809 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02694809 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02694809 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03668977 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortified balanced protein-energy.
Description: The exact form of this supplement will be selected in Phases one and two but its composition will be in conformance with the recommendations from the expert panel convened by the B\&MGF on nutritional supplementation in pregnancy (Expert Consultation, 2016). The calorie content will be approxmately 400 Kcal/day with approximately 14 g of protein.
Study NCT03100019 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03468543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine Hydrochloride MR Prototype Capsule Formulation B
Description: Memantine HCl MR capsule formulation will be administered orally in a single dose
Study NCT03468543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine Hydrochloride MR Prototype Capsule Formulation C
Description: Memantine HCl MR capsule formulation will be administered orally in a single dose
Study NCT03468543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine Hydrochloride MR Prototype Capsule Formulation D
Description: Memantine HCl MR capsule formulation will be administered orally in a single dose
Study NCT01084252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab SAR650984
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous
Study NCT01084252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous
Study NCT01084252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT00666341 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rPhleum
Description: Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 3 (80 μg)
Study NCT00666341 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rPhleum
Description: Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 4 (120 μg)
Study NCT01837095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: POL6326
Description: POL6326 will be given by i.v. infusion over 2 hours. Treatment will occur on days prior to, on the day of and on days after treatment with eribulin
Study NCT03468543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine Hydrochloride MR Prototype Capsule Formulation E
Description: Memantine HCl MR capsule formulation will be administered orally in a single dose
Study NCT03468543 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: MRI will be performed on specified days according to protocol
Study NCT01249118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0973 IV Infusion
Description: IV infusion.